MKS Instruments vs Novavax Inc — how do they compare? MKS Instruments trades at $264.5 (market cap $17.61B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: MKS Instruments is far larger — about 9.7× Novavax Inc's market cap, and MKS Instruments pays a 0.38% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MKS Instruments for 7 Days and Novavax Inc for 59 Days on average.
| MKSI | NVAX | |
|---|---|---|
Market Cap | $17.61B | $1.82B |
Volume | 1,275,355 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $444.80 | $12.75 |
52-Week Low | $121.26 | $6.22 |
Typical Hold Time | 7 Days | 59 Days |
Enterprise Value | $21.18B | $1.39B |
Dividend Yield | 0.38% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
MKS develops instruments, systems, and process control solutions for advanced manufacturing. Its technologies serve semiconductor manufacturing, electronics and packaging, photonics, and specialty industrial applications.
Read more on MKSI →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →